Which statement is most accurate regarding potential clozapine toxicities and their management?
The answer is A. These are the most updated guidelines for ANC monitoring (released in October 2015). Rechallenge is not absolutely contraindicated and can be considered after a risk-benefit discussion, although approximately one-third of patients may experience a repeat (and more severe) dyscrasia. Filgrastim is best reserved for short term use. Older patients and patients with a lower ANC at clozapine initiation appear to be at higher risk of agranulocytosis. The absolute risk of agranulocytosis with clozapine is 0.8%, and 2.9% for neutropenia.